HC Wainwright reiterated their buy rating on shares of Stealth BioTherapeutics (NASDAQ:MITO) in a research note released on Friday, Stock Target Advisor reports. HC Wainwright currently has a $21.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on the company. Nomura set a $28.00 price target on Stealth BioTherapeutics and gave the stock a buy rating in a research note on Friday, October 18th. Jefferies Financial Group set a $9.00 price target on Stealth BioTherapeutics and gave the stock a hold rating in a research note on Tuesday, October 15th. Zacks Investment Research raised Stealth BioTherapeutics from a sell rating to a hold rating in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald began coverage on Stealth BioTherapeutics in a report on Friday, September 27th. They set an overweight rating and a $18.00 price objective on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Stealth BioTherapeutics currently has a consensus rating of Buy and a consensus price target of $21.86.

Stealth BioTherapeutics stock traded up $0.51 during mid-day trading on Friday, hitting $7.66. The company’s stock had a trading volume of 2,511 shares, compared to its average volume of 23,910. The firm’s 50 day moving average is $6.71 and its 200 day moving average is $10.26. The company has a market cap of $302.66 million and a PE ratio of -5.43. The company has a debt-to-equity ratio of 2.19, a current ratio of 1.40 and a quick ratio of 1.40. Stealth BioTherapeutics has a 52-week low of $4.97 and a 52-week high of $20.99.

Stealth BioTherapeutics (NASDAQ:MITO) last announced its quarterly earnings data on Thursday, November 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). As a group, analysts forecast that Stealth BioTherapeutics will post -0.2 EPS for the current year.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Read More: The mechanics of the bid-ask spread in trading

Analyst Recommendations for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.